Show simple item record

dc.contributor.authorWu, Y
dc.contributor.authorGao, F
dc.contributor.authorQi, J
dc.contributor.authorBi, Y
dc.contributor.authorFu, L
dc.contributor.authorMohan, S
dc.contributor.authorChen, Y
dc.contributor.authorLi, X
dc.contributor.authorPinto, BM
dc.contributor.authorVavricka, CJ
dc.contributor.authorTien, P
dc.contributor.authorGao, GF
dc.description.abstractInfluenza virus neuraminidase (NA) drug resistance is one of the challenges to preparedness against epidemic and pandemic influenza virus infections. NA N1- and N2-containing influenza viruses are the primary cause of seasonal epidemics and past pandemics. The structural and functional basis underlying drug resistance of the influenza virus N1 NA is well characterized. Yet drug resistance of the N2 strain is not well understood. Here, we confirm that replacement of N2 E119 or I222 results in multidrug resistance, and when the replacements occur together, the sensitivity to NA inhibitors (NAI) is reduced severely. Using crystallographic studies, we showed that E119 replacement results in a loss of hydrogen bonding to oseltamivir and zanamivir, whereas I222 replacement results in a change in the hydrophobic environment that is critical for oseltamivir binding. Moreover, we found that MS-257, a zanamivir-oseltamivir hybrid inhibitor, is less susceptible to drug resistance. The binding mode of MS- 257 shows that increased hydrogen bonding interactions between the inhibitor and NA active site anchor the inhibitor within the active site and allow adjustments in response to active-site modifications. Such stability is likely responsible for the observed reduced susceptibility to drug resistance. MS-257 serves as a next-generation anti-influenza virus drug candidate and serves also as a scaffold for further design of NAIs.
dc.publisherAmerican Society for Microbiology
dc.relation.ispartofjournalJournal of Virology
dc.subject.fieldofresearchBiological sciences
dc.subject.fieldofresearchAgricultural, veterinary and food sciences
dc.subject.fieldofresearchBiomedical and clinical sciences
dc.titleResistance to mutant group 2 influenza virus neuraminidases of an oseltamivir-zanamivir hybrid inhibitor
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationWu, Y; Gao, F; Qi, J; Bi, Y; Fu, L; Mohan, S; Chen, Y; Li, X; Pinto, BM; Vavricka, CJ; Tien, P; Gao, GF, Resistance to mutant group 2 influenza virus neuraminidases of an oseltamivir-zanamivir hybrid inhibitor, Journal of Virology, 2016, 90 (23), pp. 10693-10700
gro.hasfulltextNo Full Text
gro.griffith.authorPinto, Mario M.

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record